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Abstract: One of the main pharmacological problems today in the treatment of chronic 
inflammation diseases consists of the fact that anti-inflammatory drugs usually exhibit side 
effects. The natural products offer a great hope in the identification of bioactive lead 
compounds and their development into drugs for treating inflammatory diseases. 
Computer-aided drug design has proved to be a very useful tool for discovering new drugs 
and, specifically, Molecular Topology has become a good technique for such a goal.   
A topological-mathematical model, obtained by linear discriminant analysis, has been 
developed for the search of new anti-inflammatory natural compounds. An external 
validation obtained with the remaining compounds (those not used in building up the 
model), has been carried out. Finally, a virtual screening on natural products was performed 
and 74 compounds showed actual anti-inflammatory activity. From them, 54 had been 
previously described as anti-inflammatory in the literature. This can be seen as a plus in the 
model validation and as a reinforcement of the role of Molecular Topology as an efficient 
tool for the discovery of new anti-inflammatory natural compounds. 
Keywords:  Molecular Topology; virtual screening; natural; anti-inflammatory; linear 
discriminant analysis 
 
OPEN ACCESSInt. J. Mol. Sci. 2011, 12                 
 
 
9482
1. Introduction 
One of the biggest pharmacological problems today is the treatment of chronic inflammations. 
Diseases like chronic asthma, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease 
(IBD), and psoriasis, are strongly debilitating and are becoming increasingly common in our aging 
society. Rheumatoid arthritis and osteoarthritis are the major inflammatory diseases affecting people 
worldwide. Increases in life expectancy and aging populations are expected to make osteoarthritis the 
fourth leading cause of disability by the year 2020. Moreover, epidemiological studies have identified 
chronic infections and inflammation as major risk factors for various types of cancer [1]. 
Several classes of drugs, such as corticosteroids, NSAIDs, and biologics, are used to treat the 
inflammatory disorders. The main problem is that these drugs possess several adverse effects or are too 
expensive to be used. Corticosteroids have long been used for the management of rheumatoid arthritis 
and IBD’s diseases, but they suffer from some serious adverse effects, such as Cushing’s habitus, 
hypertension, hyperglycemia, muscular weakness, increased susceptibility to infection, osteoporosis, 
glaucoma, psychiatric disturbances, growth arrest, etc. 
Likewise, the side effects associated with the use of NSAIDs, such as gastrointestinal ulceration and 
bleeding, and platelet dysfunction, are several and common, and because of the largest use (and abuse) 
of this class of drugs, they represent a big problem at the moment to treat chronic inflammations. 
The coxibs also exhibited cardiovascular side effects due to inhibition of prostacyclin formation in 
the infarcted heart, tipping the balance of prostacyclin/thromboxane, coupled with a diminution in 
prostacyclin in heart muscle. Therefore, it is quite clear that the clinically used anti-inflammatory 
drugs suffer from the disadvantage of side effects and high cost of treatment (in case of biologics) [1]. 
There is a valid alternative to these drugs, represented by natural products, which offer a great hope 
in the identification of bioactive lead compounds and their development into drugs for treating 
inflammatory diseases [1]. Is known that plants have been the basis of many traditional medicine 
systems throughout the world for thousands of years and they represent an exhaustive source of “raw 
materials” in order to find and synthesize new molecules with pharmacological activity [1]. 
Natural Products (NP) are classified into three groups: NPs, semi-synthetic NPs or NP-derived [2]. 
The value of natural products can be assessed by the rate of introduction of new chemical entities of 
wide structural diversity, including serving as templates for semisynthetic and total synthetic 
modification. 
An analysis of the origin of the drugs developed between 1981 and 2002 showed that natural 
products or natural product-derived drugs comprised 28% of all new chemical entities (NCEs) 
launched onto the market. In addition, 24% of these NCEs were synthetic or natural mimic compounds, 
based on the study of pharmacophores related to natural products. This combined percentage (52% of 
all NCEs) suggests that natural products are important sources for new drugs and are also good lead 
compounds suitable for further modification during the drug development process. Scrutiny of medical 
indications by source of compounds has demonstrated that natural products and related drugs are used 
to treat 87% of all categorized human diseases (48/55) [3]. 
It is noteworthy that Natural Products have played a pivotal role in immunosuppression drug 
discovery as shown by the launch of the NPs cyclosporin 72 (1983), tacrolimus (1993), sirolimus 10 
(1999) and mycophenolate sodium (2003), and the semi-synthetic NPs mycophenolate mofetil (1995), Int. J. Mol. Sci. 2011, 12                 
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everolimus 129 (2004) and fingolimod (2010). In addition, the NP-derived aspirin (acetylsalicylic acid) 
discovered in the late 1890s is still used widely as an analgesic and anti-inflammatory, while 
corticosteroids and b2 agonists modeled on adrenaline (e.g., salbutamol and salmeterol) are used to help 
control asthma [2]. A total of 13 NP and NP-derived drugs were approved for marketing worldwide 
from 2005 to 2007 , with 5 being classified as NPs, 6 semi-synthetic NPs and 2 NP-derived drugs [2]. 
Despite this statistic, pharmaceutical companies have embraced the era of combinatorial chemistry, 
neglecting the development of natural products as potential drug candidates in favor of high-throughput 
synthesis of large compound libraries [4]. The main reasons for this include the incompatibility of 
natural product libraries with high-throughput screening and the marginal improvement in core 
technologies for natural product screening in the late 1980s and early 1990s [5]. Luckily, during the 
last years, the development of new technologies has revolutionized the screening of natural products. 
Applying these technologies compensates for the inherent limitations of natural products and offers a 
unique opportunity to re-establish natural products as a major source for drug discovery [5]. 
We have to understand that the natural product landscape offers, not only the direct introduction of 
natural products into the drug discovery process, but more often, natural products serve themselves as 
lead agents, providing the chemist with a structural platform which can be elaborated upon, or simplified, 
to yield a therapeutically valuable pharmaceutical [6]. They offer unmatched chemical diversity with 
structural complexity and biological potency. Natural product resources, especially from the marine 
environment, are resourceful and largely unexplored [7]. 
Another key point relating to natural products is that we can start from the original natural product 
and develop an analog strategy which permits us to create or modify new molecules with biological or 
pharmacological activity. As for the anti-inflammatory natural products, they have been discovered 
based on ethnopharmacological observations, thanks to some new strategies in chemical investigation. 
In this regard, through the use of topological descriptors, they could provide new potential drug targets. 
In the late 1980s, computational chemistry sped up the drug discovery process. Afterwards, 
combinatorial chemistry (including molecular evolution, multiple parallel synthesis, etc.) arrived 
combined with High Throughput Screening (HTS), in the mid-1990s. 
Virtual Screening, or in silico screening, is an approach attracting increasing interest in the 
pharmaceutical industry as a productive and cost-effective technology for the search of novel hit or 
lead compounds [8–10]. 
The principles involve the computational analysis of chemical databases, to identify those compounds 
that are most likely to show a given biological activity. Of course, these ideas are not new, but have 
been pursued for years by groups working in drug design and discovery. However, the availability of 
inexpensive high-performance computing platforms has transformed these processes in such a way that, 
at present, increasingly complex and more accurate analyses can be performed on a very large data set. 
The topological virtual screening is based on the analysis of a chemical diversity of molecules [8], 
which enables the selection of the best potential molecular choices. In principle, the molecules are not 
classified according to their biological activity, but depicted by their topological indices (TIs) and after 
a computational study of their structures, only those ones complying with a desired topological model 
are chosen for further development. Int. J. Mol. Sci. 2011, 12                 
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Then a model comes from a linear discriminant analysis (LDA) containing two sets of structures: 
One of them has a well-defined pharmacological activity, and the other one, is built from structures 
showing no this biological activity. 
The resulting model, associated with the desired pharmacological activity, generates a set of 
topological descriptors capable of differentiating potentially active compounds from those lacking activity. 
The method above represents a rather detailed and relevant framework to search for leads, 
prioritizing the selection of compounds that are advisable to be tested in a biological assay. It offers a 
new option, a new method that shows itself to be powerful in facing the hunt for new targets, new lead 
compounds that finally enable the securing of new drugs. 
This report deals with the search of natural anti-inflammatory compounds by using a database of 
natural products. The research team has gained experience in discovering new drugs applying Molecular 
Topology, and has developed several models in the field of anti-inflammatory compounds [11–13]. 
2. Materials and Methods 
2.1. Analyzed Compounds 
The model for searching new natural anti-inflammatory compounds was made up of 412 natural 
compounds, 123 active as anti-inflammatories and 289 inactive. Almost all the active compounds were 
from a paper reported by Kontogiorgis et al. [14] and the rest of them active and inactive from the 
collection Pure Natural Products from MicroSource database [15]. Compounds conforming the test set 
and Virtual screening were also achieved from these sources. Compounds forming the training set are 
shown in Supplementary material, Annex I. All sets of compounds are characterized by a large 
structural diversity 
2.2. Molecular Descriptors 
The 2D structure of each compound was drawn using the ChemDraw Ultra package [16]. Each 
compound was characterized by a set of 436 topological indices, standing among them the topological 
charge indices, quotients and differences between nonvalence and valence connectivity indices, 
topological and 2D autocorrelation descriptors. All indices were calculated with Dragon software [17]. 
In the supplementary material, Annex I, the TI’s values are given for all compounds of the model. 
2.3. Modeling Techniques 
Linear discriminant analysis (LDA) is a pattern recognition method which provides a classification 
model based on the combination of variables that best predict the category or group to which a given 
compound belongs. We built up a natural compounds database where all compounds were allocated 
into an active or inactive group according to their anti-inflammatory activity. The LDA was then 
applied to these two groups to obtain a discriminant function (DF) with the statistical software 
Statistica 9.0 [18]. The independent variables were the TIs, and the discriminatory property was the 
anti-inflammatory activity. The discriminant capability was assessed as the percentage of correct 
classifications in each set of compounds. The classification criterion was the minimal Mahalanobis 
distance (distance of each case to the mean of all the cases in a category). The quality of the Int. J. Mol. Sci. 2011, 12                 
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discriminant function was evaluated using the Wilks parameter, λ, which was obtained by multivariate 
analysis of variance that tests the equality of group means for the variable in the discriminant model. 
The method used to select the descriptors was based on the Fisher-Snedecor parameter (F), which 
determines the relative importance of candidate variables. The variables used to compute the linear 
classification function are chosen in a stepwise manner: at each step, the variable that makes the largest 
contribution to the separation of the groups is entered into the discriminant equation (or the variable 
that makes the smallest contribution is removed). 
The validation of the selected function was done using an external test set. Compounds that comprise 
the test set, were randomly selected from approximately 20% of the data, and were not used in the set 
up of the DF equation. 
Another important parameter that usually provides a balanced evaluation of the model’s prediction 
is the Matthews correlation coefficient (MCC) [19]. This coefficient is based on the fact that in any 
prediction process there can be four different possibilities to account for: 
TP (True positive): Active compounds correctly classified or predicted. 
FP (False positive): Inactive compounds classified as anti-inflammatory. 
TN (True negative): Inactive compounds correctly classified. 
FN (False negative): Anti-inflammatory compounds classified as inactive. 
It is clear therefore, that any single number that represents the predictive power of the method must 
account for all the possibilities listed above. MCC fulfils these requirements. Matthews’ coefficient is 
defined as shown in Equation (1): 
   
     FN TP FP TP FP TN FN TN
FN FP TN TP
MCC
      
  
   (1)
The Matthews correlation coefficient ranges from −1 ≤ MCC ≤ 1. A value of MCC = 1 indicates the 
best possible prediction, in which every compound in the model was correctly classified, whereas if 
MCC = −1 then we are in the worst possible case (or anti-correlation), where no one single compound 
has been correctly labeled. Finally, a Matthews correlation coefficient of MCC = 0 is what would be 
expected for a random prediction. 
2.4. Pharmacological-Activity Distribution Diagrams 
A pharmacological distribution diagram (PDD) is a graphical representation that provides a 
straightforward way of visualizing the regions of minimum overlap between active and inactive 
compounds, as well as the regions in which the probability of finding active compounds is at a 
maximum [20]. 
Actually, a PDD is a frequency distribution diagram of dependent variables in which the ordinate 
represents the expectancy (probability of activity) and the abscissa represents the DF values in the 
range. For an arbitrary range of values of a given function, an “expectancy of activity” can be defined 
as Ea = a/(i + 1),where “a” is the number of active compounds in the range divided by the total number 
of active compounds and “i” is the number of inactive compounds in the interval divided by the total 
number of inactive compounds. The expectancy of inactivity is defined in a symmetrical way, as   
Ei = i/(a + 1). Presented with these diagrams, it is easy to visualize the intervals in which there is a Int. J. Mol. Sci. 2011, 12                 
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maximum probability of finding new active compounds and a minimum probability of finding   
inactive compounds. 
2.5. Topological Virtual Screening 
The topological model resulting from DF function was used to find new natural anti-inflammatory 
compounds. A group of compounds from MicroSource Pure Natural Products Collection database, that 
has not been employed neither in the training set nor in the test set, were screened for the search of 
potential new anti-inflammatory natural compounds. 
3. Results and Discussion  
3.1. Similarity Study 
A study of compounds’ similarity was previously carried out in order to guarantee that no simple or 
evident structural features are discriminating between the molecules that make up the data set. Thus, 
molecular weight, MW, partition coefficient, logP, (values estimated for log P with Dragon software, [17]) 
and Randic index, 
1χ, have been calculated for all compounds in the database. These descriptors give 
us information about the molecular size, lipophilia and molecular branching, respectively. 
Figure 1. Average, maximum and minimum values (gray, white and black bars, 
respectively) obtained with molecular weight, MW, partition coefficient, logP, and Randic 
index, 
1χ for the training and test sets of compounds. 
 
For these parameters in the training set, we obtained an average value of 300 (MW), 2.66 (logP) and 
10.4 (
1χ for the active compounds, whereas average values of 372 (MW), 2.7 (logP) and 10.9 (
1χ) 
were obtained for the inactive ones. Hence, the set is well balanced and no obvious structural 
differences are expected to distort the study. The results obtained with the test set are similar to those 
of the training set (see Figure 1). Int. J. Mol. Sci. 2011, 12                 
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If we compare these values to those obtained for the selected set of anti-inflammatory natural 
compounds,  i.e., 276.75 (MW), 2.00 (logP) and 8.12 (
1χ) value, we can see that the predicted   
anti-inflammatory natural compounds show lower values of the three parameters, and therefore the 
structures selected from natural compounds are diverse from those already well-known and used in the 
training set. 
3.2. Mathematical Modeling 
The mathematical model was developed from a training set including 412 compounds, with 
heterogeneous molecular structures. Even if the number of active compounds (123 molecules) and 
inactive (289) that comprise the training set were not similar in number, this was offset by the 
construction of a model by which every compound has the same statistical weight. 
The discriminant Equation (2), is shown below. This equation is comprised of five   
independent variables: 
DF = −0,005 × TI1 + 5,666 × ATS7m − 11,820 × ATS4v −  
9,178 × ATS7v + 28,912 × ATS1p −42,202 
(2)
N = 412, F = 46, and λ =0.663. 
The molecular descriptors in Equation (2) are described in Table 1 along with their definitions  
and references. 
Table 1. Descriptors used in this model. 
Symbol Name Ref. 
TI1  first Mohar index  21 
ATS7m 
2D Broto-Moreau autocorrelation 
22 
of a topological structure-lag7⁄weighted by atomic masses 
ATS4v 
2D Broto-Moreau autocorrelation 
[23] 
of a topological structure-lag4⁄weighted by Van der Waal volumes 
ATS7v 
2D Broto-Moreau autocorrelation 
[23] 
of a topological structure-lag7⁄weighted by Van der Waal volumes 
ATS1p 
2D Broto-Moreau autocorrelation 
[23] 
of a topological structure-lag4⁄weighted by Atomic polarizabilities 
According to Equation (2), a compound should be classified as active if DF > 0.78, otherwise it is 
labeled as inactive. 
By applying this criterion to the training set (412 compounds), (see supplementary material annex I 
for details), 61 out of 123 experimentally active compounds were correctly classified as such (50% 
accuracy), and 284 out of 289 experimentally inactive compounds were also well classified (98% 
accuracy) as can be seen in Table 2. Altogether, the average of correct classification for the entire set 
of compounds (active plus inactive) was 74%. 
   Int. J. Mol. Sci. 2011, 12                 
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Table 2. Classification matrix obtained through the selected discriminant function (DF) for 
the training and test set. 
  Percent-Correct 
Compounds 
Classified as Active 
Compounds 
Classified as Inactive
Training Set 
Active Group  50 61  62 
Inactive Group  98 5  284 
Test Set 
Active Group  59 24  17 
Inactive Group  86 6  37 
The following formula was used to calculate the percentage of correctly classified compounds 
within a particular category (active or inactive) as shown in Equation (3): 
Classification accuracy (%) = (CCC × 100/TNC)  (3)
where CCC is correctly-classified compounds and TNC is a total number of compounds. 
Regarding the Matthews correlation coefficient, which returns a value between −1 and +1, our 
model shows a value of 0.6, what ensures its reliability. 
Furthermore, the Matthews correlation coefficient was calculated in a slightly different way, i.e., by 
adding +1 to each scale value, in this way the outcome it could be expressed as % accuracy. In other 
words, 0 would mean no correlation at all, 1 represents 50% and 2 stands for the maximum correlation 
(100%). By doing so, our model’s yield was 80% (MCC modified = 1.6). 
To establish the adequate range of activity, we analyzed the pharmacological distribution diagram 
obtained with the discriminant function, DF. 
Looking at Figure 2, we can appreciate that, all the compounds studied show DF values in the range 
8 > DF > −7. Outside these ranges the compound’s classification is uncertain and it is labeled as  
“not-classified” (outliers), NC. 
Figure 2. Pharmacological distribution diagram for natural anti-inflammatory compounds 
obtained using the discriminant function DF. (The black color represents the compounds 
with anti-inflammatory activity and the white color, the compounds without it). 
 Int. J. Mol. Sci. 2011, 12                 
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An easy way to evaluate the quality of the function above is to apply it into an external group. In 
our case, this group was made up of 84 compounds (41 active and 43 inactive) which had not been 
included for DF calculation, what is about 20% of the data. Table 3 outlines the results of the prediction 
obtained for every compound of the test set. 
Table 3. Results of prediction of anti-inflammatory activity obtained applying the linear 
discriminant analysis to the test set. 
Compound TI1  ATS7m ATS4v ATS7v ATS1p 
DF Class.
Ref. 
Value Pred.
Active Group 
2',β-DIHYDROXYCHALCONE 25.6  2.79  2.81  2.57  2.91  0.82  A [24] 
3,7-DIMETHOXYFLAVONE 49  3  3.27  2.73  3.01  −2.19 I  [25] 
4-METHYLESCULETIN 11.21 1.02  2.51  0.23  2.59  6.44  A [26] 
ANISODAMINE 66.85 3.2  3.02  2.93  3.05  1.22  A [27] 
BERGENIN 51.11 3.32  3.37  2.52  2.97  −0.82 I [28,29]
β-CARYOPHYLLENE ALCOHOL  23.75 0  3.12  0  2.92  5.13  A [30] 
BICUCULLINE (+)  158.89 3.69  3.66  3.24  3.25  −0.95 I [31,32]
BOLDINE 73.83 3.38  3.7  2.83  3.16  −1.75 I [33,34]
BRAZILEIN 58.35 2.98  3.35  2.24  3.08  3.31  A [35,36]
CAMPTOTHECIN 113.6 3.45  3.64  3.14  3.27  −0.33 I [37,38]
CAPSAICIN 0  3.01  2.95  2.71  3  1.8  A [39,40]
CARNOSIC ACID  54.11 2.93  3.81  2.68  3.21  −2.66 I  [41] 
CARVACROL 0  0  2.08  0  2.44  3.68  A [14] 
DIHYDROTANSHINONE I  57.02 2.66  3.51  2.4  3.13  −0.49 I [42,43]
ELLAGIC ACID  56.29 2.61  3.43 1.72 3.02 3.35  A [44,45]
EPIAFZELECHIN (2R,3R)(−) 44.79 3.02  3.06  2.53  2.98  1.45  A [46] 
EUPHOL 146.22 3.66  4.11  3.61  3.54  −1.62 I  [47] 
GALLIC ACID  0  0  1.93  0  2.33  2.36  A [48] 
GENISTEIN 44.57 2.88  3.09  2.45  2.98  1.15  A [14] 
HARMALINE 26.93 1.98  2.93  1.48  2.8  1.62  A [49] 
HEMATEIN 63.65 3.11  3.4  2.34  3.1  3.01  A [50,51]
HIERACIN 53.56 3.3  3.17  2.72  3.03  1.38  A [52] 
IRIGENIN TRIMETHYL ETHER  90.88 3.73  3.75  3.27  3.17  −4.15 I  [53] 
ISOLIQUIRITIGENIN 29.12 2.87  2.78  2.61  2.94  2  A [54] 
KOPARIN 2'-METHYL ETHER  59.21 3.2  3.37  2.81  3.05  −1.78 I  [55] 
KYNURENINE 0  2.45  2.51  1.7  2.61  1.89  A [56] 
LAWSONE 9.48  0  2.43  0  2.59  4  A [57] 
LUTEOLIN GLUCOSIDE  171.97 4.01  3.57  3.45  3.35  2.44  A [14] 
MADECASSIC ACID  189.69 4.04  4.43  3.75  3.63  −2.1 I  [58] 
METHYL ORSELLINATE  0  0.85  2.39 0.41 2.42 0.59 I [59,60]
N-METHYLANTHRANILIC ACID  0  0  2.14  0  2.32  −0.42 I  [61] 
OLEANOLIC ACID  163.48 3.85  4.28  3.68  3.59  −1.63 I  [14] 
OUABAIN 358.36 4.4  4.26  3.88  3.66  0.84  A  [62] 
p-HYDROXYCINNAMALDEHYDE 0  1.3  1.95  0.71  2.39  4.75  A [63,64]
QUERCETIN 52.38 3.27  3.2  2.67  3.03  1.29  A [65] 
QUERCETIN TETRAMETHYL 
(5,7,3',4') ETHER 
74.79 3.59 3.54 3.09 3.11  −2.49  I [14] 
SANTONIN 31.04 1.86  3.2  1.19  2.94  4.27  A [66] Int. J. Mol. Sci. 2011, 12                 
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Table 3. Cont. 
Compound TI1  ATS7m ATS4v ATS7v ATS1p 
DF Class.
Ref. 
Value Pred.
Active Group 
SILIBININ 243.99 4.1  3.85  3.61  3.48  1.68  A [67–69]
TECTORIGENIN 53.39 3.12  3.26  2.68  3.03  −0.42 I [70,71]
UMBELLIFERONE 8.36  0  2.12 0 2.47  4.15  A [14] 
UVAOL 153.27 3.74  4.29  3.61  3.58  −2.13 I  [72] 
Inactive Group 
2-METHYL GRAMINE  13.23 1.1  2.73  1.1  2.65  −1.78 I  - 
3-DEACETYLKHIVORIN 285.72 4.57  4.44  4.14  3.62  −3.59  I - 
3-PINANONE OXIME  9.02  0  2.19  0  2.56  5.84  A  - 
ASARYLALDEHYDE 0  1.2  2.61  0.92  2.41  −4.9  I - 
BAEOMYCESIC ACID  47.58 3.65  3.52  3.25  3.16  −1.82  I - 
BOVINOCIDIN  
(3-NITROPROPIONIC ACID) 
−8.58 0 1.01 0 1.63  −6.92  I - 
CHOLEST-5-EN-3-ONE 128.51 3.42  3.89  3.37  3.45  −0.65 I  - 
CONESSINE 112.88 3.25  3.84  3.16  3.36  −1.57 I  - 
CRASSIN ACETATE  37.49 3.91  3.71  3.52  3.23  −3.06  I - 
CRINAMINE 78.42 2.9  3.48  2.38  3.09  0.22  I  - 
DEACETOXY-7-OXISOGEDUNIN 188.23 3.82 4.25 3.46  3.5  −2.23  I - 
DEOXYANDIROBIN 161.25 3.95  4.14  3.62  3.47  −2.48  I - 
DIPHENYLUREA 21.73 2.4  2.5  2.4  2.77  −0.23 I  - 
DUARTIN. DIMETHYL ETHER  76.8  3.39  3.6  3.04  3.11  −3.9  I - 
EPI(13)TORULOSOL 30.87 3.08  3.56  2.87  3.13  −2.72  I - 
EUDESMIC ACID  0  1.3  2.7  0.71  2.45  −2.3  I - 
EVOXINE 76.98 3.47  3.43  2.99  3.08  −1.8 I  - 
GLUCITOL-4-GUCOPYANOSIDE 0  3.66  3.06  2.82  2.83  −1.71 I  - 
HEXAMETHYLQUERCETAGETIN 88.94 3.82  3.75 3.33 3.17  −4.27  I - 
ISOOSAJIN 153.22 3.79  3.85  3.61  3.42  −1.22 I  - 
JUAREZIC ACID  0  2.23  2.2  1.8  2.56  1.88  A  - 
KHAYASIN 274.26 4.48  4.38  4.11  3.65  −2.18  I - 
LEOIDIN 68.47 3.83  3.74  3.25  3.22  −1.74 I  - 
LOMATIN 31.81 2.35  3.04  1.99  2.88  −0.07 I  - 
MEDICARPIN 56.7  2.78  3.17  2.43  3.01  0.37  I  - 
MEROGEDUNIN 72.24 3.21  3.94  2.75  3.27  −1.63 I  - 
METAMECONINE 12.34 0.85  2.5  0.41  2.5  1.53  A  - 
METHYL EVERNINATE  0  1.61  2.56  0.93  2.46  −0.68 I  - 
METHYL ROBUSTONE  146.49 3.65  3.68  3.34  3.3  −1.03 I  - 
N-METHYLISOLEUCINE  −11.17 0 2.05 0 2.1  −5.69  I - 
PLECTOCOMINE METHYL ETHER  23.69 1.52  2.76  1.21  2.74  1.61  A  - 
PODOTOTARIN 346.77 4.54  4.56  4.38  3.85  −1.06 I  - 
PRENYLETIN 24.04 2.78  2.76  2.43  2.82  −0.07 I  - 
PTAEROXYLIN 35.11 2.49  3.15  2.26  2.93  −1.55 I  - 
RETUSOQUINONE 0  1.3  2.35  0.71  2.52  3.8  A  - 
RHETSININE 94.88 3.23  3.46  2.98  3.19  −0.36 I  - 
RHODINYL ACETATE  −25.56 2.04 2.36 1.8 2.52  −2.14  I - 
ROBUSTIC ACID  114.56 3.69  3.71  3.36  3.28  −1.77 I  - 
SARMENTOSIDE B  484.87 4.66  4.42  4.15  3.75  −0.04 I  - Int. J. Mol. Sci. 2011, 12                 
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Table 3. Cont. 
Compound TI1  ATS7m ATS4v ATS7v ATS1p 
DF Class.
Ref. 
Value Pred.
Inactive Group 
SENECRASSIDIOL 6-ACETATE  41.44 2.6  3.42  2.06  3.04  0.77  I  - 
THEANINE  −17.76 1.76 2.01 1.31 2.22  −3.61  I - 
TROPINE 5.68  0  1.22  0  2.34  10.88  N.C.  - 
XANTHOXYLIN 0  1.2  2.63  0.92  2.46  −3.75  I - 
As we can appreciate in Table 2, the success rate is increased in the active group up to 59% (24 of 
41 compounds analyzed were correctly classified). In the case of the inactive group belonging to the 
test set, there are only six compounds misclassified; the rate of correct compounds was 86% (37 of 43 
compounds analyzed were correctly classified), indicating that DF has a high specificity in recognizing 
inactive compounds, because it has the capability to predict if an inactive compound is actually 
inactive. Hence, we can ensure that the number of “false active” is going to be minimumized. 
Furthermore, although DF will lead to the loss of some of the active compounds, the important point is 
that there is a lower risk of including false active compounds when we carry out a database screening 
searching for anti-inflammatory natural compounds. 
As illustrated in Table 3, there is just one outlier or uncertain compound in the inactive group, 
namely Tropine, whose DF value exceeds the range of application of the model. 
In Equation (2), there are topological descriptors which evaluate the molecular bonds, TI1, the atomic 
masses, ATS7m, Van der Waal volumes, ATS4v and ATS7v, and finally, the atomic polarizabilities of 
the molecules, ATS1p. 
Although it is not easy to unfold the structural features explaining the discriminant equation obtained, 
some insight can be gained on the basis of the most relevant indices in the regression equation, namely 
TI1, ATS7m, ATS4v, ATS7v and ATS1p. Each one of these indices refers to a specific physical or 
chemical property of the molecule. 
For example, the Moreau-Broto (ATS) autocorrelation descriptors represent the interactions between 
atoms at topological distance k, (lag k), for a particular atomic property (weighting factor). In our case, 
the weighting factors are basically the atomic polarizability, the van der Waals volume and the atomic 
mass. These descriptors seem to be sensitive to the molecular branching and cyclicity. 
From a general overview of the active and inactive compounds, we can find some differences, for 
example the active compounds typically show hydroxyl groups (low mass and electronic acceptors) 
which, contrary to the inactive compounds, are placed in the molecule far away from the carbonyls. On 
the other hand, the inactive set includes compounds showing methoxy groups (higher mass and 
electronic donors). In general there are less cyclic compounds among the inactive set. See as examples 
(Figure 3), capsaicin or p-hydroxycinnamaldehyde among the actives or Rhodinyl acetate or theanine 
among the inactives. 
The active compounds often show a higher polarizability (taken into account by the index ATS1p), 
as compared to the inactive, which is compatible with their larger molecular volume and the presence 
of hydroxyl groups. Obviously the hydroxyl groups would also play a key role in molecular solubility 
and the molecule’s capability to form hydrogen bonding, which are also well known factors 
influencing the activity. Int. J. Mol. Sci. 2011, 12                 
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Figure 3. General overview of the active and inactive compounds by their structural and 
chemical properties.  
 
Given the high structural heterogenicity of the molecules used to build up the models, these results 
can be applied to large databases including natural compounds to search for new active compounds. 
3.3. Topological Virtual Screening 
Based on the model described above, a virtual screening was carried out on a database of 
heterogeneous natural compounds. We used some of the compounds of the library MicroSource Pure 
Natural Products Collection, that were not used for the construction of the model or for the external 
validation and we performed a virtual screening searching for anti-inflammatory natural compounds. 
The library composition can be obtained from the MicroSource Discovery Systems website [15]. 
As shown in Table 4, a set of 74 natural compounds were selected with a DF values between  
2 < DF < 6 with predicted activity as anti-inflammatory. Almost all of these were commercially available. 
Table 4. Group of natural compounds selected as anti-inflammatories. The indexes value 
for each compounds, the DF value and the known anti-inflammatory activity are outlined. 
Compound TI1  ATS7m ATS4v ATS7v ATS1p 
DF 
Value 
Ref. 
1,5-NORCARYOPHYLLEN-3-ONE 12.95 0  3.07  0  2.8 2.43  [73] 
2',4'-DIHYDROXYCHALCONE  
4'-GLUCOSIDE 
119.2 3.71 3.36 3.29 3.28  3.08  nr 
2-HYDROXYXANTHONE 24.98 1.73  2.85  1.39  2.82  2.58  [74] 
3-HYDROXYCOUMARIN 8.25  0  2.15  0  2.47  3.79  [75] 
3-NOR-3-OXOPANASINSAN-6-OL 24.04 0  3.03  0  2.89 5.32  nr 
alpha-TOCHOPHEROL 83.77 3.37  3.68  3.28  3.45  2.53  nr Int. J. Mol. Sci. 2011, 12                 
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Table 4. Cont. 
Compound TI1  ATS7m ATS4v ATS7v ATS1p 
DF 
Value 
Ref. 
APIIN 345.29 4.46  3.8  3.88  3.55  3.35  [76] 
AVOCADANE ACETATE  −70.27 3.07 2.96 2.76 3.01  2.16  nr 
BATYL ALCOHOL  −83.55 2.94 2.96 2.81 3.08 3.3  [77] 
BERGAPTOL 22.16 1.3  2.67  0.71  2.69  4.85  [78] 
BIXIN  −103.7 3.31 3.33 3.18 3.27  2.98  [79] 
BRAZILIN 58.35 2.98  3.35  2.24  3.08  3.31  [80] 
CANTHARIDIN 18.37 0  2.32  0  2.62  6.04  nr 
CAPSANTHIN 187.67 3.83  3.96  3.77  3.77  6.06  [81] 
CARYOPHYLLENE [t(−)] 11.37 0  2.89  0  2.77  3.75  [82] 
CEDROL 23.5  0  3.14  0  2.92  4.87  [83] 
CHAULMOOGRIC ACID  0  2.69  2.77  2.57  2.99  3.14  [84] 
CHLOROGENIC ACID  48.22 3.36  3.09  2.78  3.07  3.29  [85] 
CINEOLE 6.55  0  2.08  0  2.48  4.81  [86] 
COSMOSIIN 162.44 3.92  3.54  3.41  3.33  2.27  [87] 
COTININE 11.53 0.85  2.43  0.41  2.53  3.21  [88] 
CULMORIN 25.72 0  3.2  0  2.94  4.8  nr 
DESOXYPEGANINE 
HYDROCHLORIDE 
16.37 0 2.49 0 2.65  4.82 nr 
DIALLYL SULFIDE  −7.5 0 1.39 0 2.12  2.63 [89] 
DICTAMNINE 22.62 0  2.88  0  2.71  2.05  nr 
DIGITOXIN 1046.2 4.61  4.4  4.15  3.93  2.34  [62] 
DIGOXIN 1069.1 4.64  4.43  4.16  3.94  2.11  [62] 
DJENKOLIC ACID  −28.53 2.37 2.28 1.86 2.69  4.92  [90] 
EPOXY (1,11)HUMULENE  15.16 0  3.05  0  2.83  3.48  [91] 
GARLICIN  −9.74 0.69 1.64 0.69 2.4 5.34  [92] 
GIBBERELLIC ACID  92.61 2.83  3.8  2.26  3.27  2.08  [93] 
GUAIAZULENE 13.61 0  3  0  2.83  4.22  [94] 
GUVACINE HYDROCHLORIDE  0  0  1.32  0  2.1  2.91  nr 
HAEMATOXYLIN 63.65 3.11  3.4  2.34  3.1  3.01  nr 
HARMALOL HYDROCHLORIDE  22.47 1.65  2.81  0.87  2.77  5.94  nr 
HARMANE 19.16 0  2.76  0  2.74  4.34  [95] 
HARMOL HYDROCHLORIDE  22.47 1.65  2.81  0.87  2.77  5.94  [96] 
HARPAGOSIDE 218.6 4.16  3.56  3.65  3.4  2.86  [97] 
HELENINE 28.19 1.79  3.07  1.26  2.91  4.05  [98] 
HESPERIDIN 421.88 4.48  3.87  3.88  3.6  3.8  [99] 
HINOKITIOL 0  0  2.26  0  2.48  2.74  [100] 
HUMULENE (alpha)  0  0  3  0  2.77  2.56  [82] 
INDOLE-3-CARBINOL 7.49  0  2.09  0  2.46  4.19  [101] 
INOSITOL 0  0  1.73  0  2.28  3.12  [102] 
ISOBERGAPTENE 25.9  0.85  2.91  0.41  2.72  2.91  nr 
ISOKOBUSONE 14.57 1.3  3.12  0.71  2.83  3.55  nr 
JUGLONE 9.48  0  2.47  0  2.59  3.48  [103] 
KOBUSONE 26.62 0  3.12  0  2.85  3.35  nr 
L(+/−)-ALLIIN  −14.57 1.3 1.97  0.71  2.36  3.65 [104] 
LYCOPODINE PERCHLORATE  36.79 0  3.48  0  3.01  3.55  [105] 
MENADIONE 9.48  0  2.53  0  2.63  3.95  [106] Int. J. Mol. Sci. 2011, 12                 
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Table 4. Cont. 
Compound TI1  ATS7m ATS4v ATS7v ATS1p 
DF 
Value 
Ref. 
MENTHOL(−) 0  0  2.2  0  2.44  2.26  [107] 
MENTHONE 0  0  2.2  0  2.44  2.26  [108] 
MIMOSINE 0  2.31  2.25  1.23  2.43  3.19  [109] 
MUUROLLADIE-3-ONE 15  1.3  3.09  0.71  2.86  4.75  nr 
OCTOPAMINE HYDROCHLORIDE  0  0.94  1.94  0.3  2.36  5.54  nr 
PATULIN 7.06  0  1.81  0  2.28  2.2  [110] 
PECTOLINARIN 427.48 4.54  3.93  3.96  3.61  3.01  [111] 
PHLORIDZIN 127.51 4.08  3.47  3.57  3.31  2.28  [112] 
PICROTOXININ 68.36 2.09  3.46  1.2  3.05  5.58  nr 
PIPERINE 74.81 2.87  2.93  2.6  3  2.01  [113] 
PLUMBAGIN 10.92 0  2.67  0  2.67  3.28  [114] 
PUNCTAPORONIN B  17.9  1.41  3.3  0.57  2.91  5.6  nr 
PURPURIN 33.76 2.12  3.22  1.62  2.96  2.28  [115] 
RHAPONTIN 125.6 3.82  3.42  3.38  3.28  2.06  [116] 
RHOIFOLIN 357.18 4.51  3.85  3.93  3.57  3.3  [117] 
RUTOSIDE (rutin)  392.19 4.68  3.88  4.07  3.6  3.12  [118] 
SAFROLGLYCOL 14.58 2.26  2.4  1.4  2.54  2.79  [119] 
SCOPOLETIN 11.82 1.33  2.47  0.82  2.54  2.11  [120] 
SECURININE 31.65 0.85  3.02  0.41  2.85  5.28  nr 
SHIKIMIC ACID  0  0  1.93  0  2.33  2.36  [121,122]
THYMOQUINONE 0  0  2.31  0  2.48  2.11  [123] 
TRYPTAMINE 9.75  0.77  2.38  0.53  2.56  3.05  [124] 
XANTHURENIC ACID  13.51 1.3  2.65  0.71  2.64  3.73  [56] 
nr (is not referenced as an anti-inflammatory in literature). 
As illustrated in the Table 4, most of the compounds selected had been described previously as  
anti-inflammatory in the literature (55/74) (see column 9), which is highly encouraging and represents 
an extra proof of the model’s performance. It is pretty clear that there are many ways of applying the 
model described herein to the search for new anti-inflammatory natural compounds. Although 19 out 
of the 74 compounds do not show anti-inflammatory activity, one cannot be sure if this is because of 
their inactivity or the absence of laboratory tests developed by someone. So it will be an attractive 
challenge for us to test these compounds and see if some of them would indeed show anti-
inflammatory activity. 
Virtual screening is increasingly gaining acceptance in the pharmaceutical industry as a cost-effective 
and timely strategy for analyzing very large chemical data set. This procedure is computationally 
intensive for analyzing large databases and it provides the most detailed basis for determining which 
compounds are likely to be potent hits or leads. The results outlined here demonstrate not only that the 
Topological Virtual Screening could accurately reproduce the well-known pharmacological activity, 
but also represent a new step forward in the pathway to demonstrate the high efficiency of the in silico 
methods based in Molecular Topology. Int. J. Mol. Sci. 2011, 12                 
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4. Conclusions  
The joint use of topological-structural descriptors of compounds and a statistical treatment based on 
discriminant analysis has been demonstrated as a very efficient methodology for the selection of new 
natural compounds with anti-inflammatory activity. The mathematical model obtained can readily be 
applied to the search of new natural compounds in large databases or even for drug design. These 
results confirm the usefulness of Molecular Topology as a powerful tool in the search for new drugs. 
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